Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
Part of paid clinical trials in Charlottesville, Virginia.
- Sponsor
- University of Virginia
- Study ID
- NCT02648633
- Phase
- PHASE1
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Stereotactic Radiosurgery — RADIATIONSubjects will receive a single large dose of radiation to one or more lesions.
- Nivolumab — DRUG3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
- Valproate — DRUGSubjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
Study Details
The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic agent nivolumab given in combination with gamma knife therapy and valproate in patients with recurrent glioblastoma, a common and lethal type of brain cancer.
Key Dates
- Start date
- May 24, 2016
- Status verified
- May 2017
- Primary completion
- Feb 21, 2017
- Completion
- Feb 21, 2017
Study Design
- Enrollment
- 4 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Nivolumab & Valproate Following G.K.Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
Primary Outcome Measure
Feasibility based on number of subjects who complete 4 doses of nivolumab [ Time Frame: At 3 months following radiosurgery ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Virginia | Charlottesville | Virginia | 22908 | - |
Find similar trials in Charlottesville, VA
By condition
By specialty
By research site
Related Studies
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)PHASE2 · Recruiting · Patrick Wen, MD · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPHASE2/PHASE3 · Recruiting · Global Coalition for Adaptive Research · Birmingham, Alabama
- Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)PHASE1/PHASE2 · Recruiting · NaviFUS Corporation · Charlottesville, Virginia